dc.contributor.author |
Borte M |
|
dc.contributor.author |
Kriván, Gergely |
|
dc.contributor.author |
Dérfalvi, Beáta |
|
dc.contributor.author |
Marodi L |
|
dc.contributor.author |
Harrer T |
|
dc.contributor.author |
Jolles S |
|
dc.contributor.author |
Bourgeois C |
|
dc.contributor.author |
Engl W |
|
dc.contributor.author |
Leibl H |
|
dc.contributor.author |
McCoy B |
|
dc.contributor.author |
Gelmont D |
|
dc.contributor.author |
Yel L |
|
dc.date.accessioned |
2017-04-13T09:32:07Z |
|
dc.date.available |
2017-04-13T09:32:07Z |
|
dc.date.issued |
2017 |
|
dc.identifier |
84995489910 |
|
dc.identifier.citation |
pagination=146-159;
journalVolume=187;
journalIssueNumber=1;
journalTitle=CLINICAL AND EXPERIMENTAL IMMUNOLOGY; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/4268 |
|
dc.identifier.uri |
doi:10.1111/cei.12866 |
|
dc.description.abstract |
A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy, safety, tolerability and pharmacokinetics of IGSC 20% were evaluated in a prospective trial in Europe in 49 patients with PIDD aged 2-67 years. Over a median of 358 days, patients received 2349 IGSC 20% infusions at monthly doses equivalent to those administered for previous intravenous or subcutaneous IgG treatment. The rate of validated acute bacterial infections (VASBIs) was significantly lower than 1 per year (0.022/patient-year, P < 0.0001); the rate of all infections was 4.38/patient-year. Median trough IgG concentrations were >/= 8 g/l. There was no serious adverse event (AE) deemed related to IGSC 20% treatment; related non-serious AEs occurred at a rate of 0.101 event/infusion. The incidence of local related AEs was 0.069 event/infusion (0.036 event/infusion, when excluding a 13-year-old patient who reported 79 of 162 total related local AEs). The incidence of related systemic AEs was 0.032 event/infusion. Most related AEs were mild, none were severe. For 64.6% of patients and in 94.8% of IGSC 20% infusions, no local related AE occurred. The median infusion duration was 0.95 (range = 0.3-4.1) h using mainly one to two administration sites [median = 2 sites (range = 1-5)]. Almost all infusions (99.8%) were administered without interruption/stopping or rate reduction. These results demonstrate that IGSC 20% provides an effective and well-tolerated therapy for patients previously on intravenous or subcutaneous treatment, without the need for dose adjustment. |
|
dc.relation.ispartof |
urn:issn:0009-9104 |
|
dc.title |
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies |
|
dc.type |
Journal Article |
|
dc.date.updated |
2017-04-05T10:44:48Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
3128812 |
|
dc.identifier.wos |
WOS:000393964800017 |
|
dc.identifier.pubmed |
27613250 |
|
dc.contributor.department |
SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|